MacroGenics, Inc. - Product Pipeline Review - 2016

Published: Jul, 2016 | Pages: 60 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

MacroGenics, Inc. - Product Pipeline Review - 2016

Summary

Global Markets Direct's, 'MacroGenics, Inc. - Product Pipeline Review - 2016', provides an overview of the MacroGenics, Inc.'s pharmaceutical research and development focus. 

The report provides comprehensive information on the therapeutics under development by MacroGenics, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of MacroGenics, Inc.
- The report provides overview of MacroGenics, Inc. including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report assesses MacroGenics, Inc.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report features MacroGenics, Inc.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons To Buy

- Evaluate MacroGenics, Inc.'s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for MacroGenics, Inc.
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding MacroGenics, Inc.'s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 5
MacroGenics, Inc. Snapshot 6
MacroGenics, Inc. Overview 6
Key Information 6
Key Facts 6
MacroGenics, Inc. - Research and Development Overview 7
Key Therapeutic Areas 7
MacroGenics, Inc. - Pipeline Review 11
Pipeline Products by Stage of Development 11
Pipeline Products - Monotherapy 12
Pipeline Products - Partnered Products 13
Partnered Products/Combination Treatment Modalities 14
Pipeline Products - Out-Licensed Products 15
Out-Licensed Products/Combination Treatment Modalities 16
MacroGenics, Inc. - Pipeline Products Glance 17
MacroGenics, Inc. - Late Stage Pipeline Products 17
Phase III Products/Combination Treatment Modalities 17
MacroGenics, Inc. - Clinical Stage Pipeline Products 18
Phase II Products/Combination Treatment Modalities 18
Phase I Products/Combination Treatment Modalities 19
MacroGenics, Inc. - Early Stage Pipeline Products 20
Preclinical Products/Combination Treatment Modalities 20
MacroGenics, Inc. - Drug Profiles 21
margetuximab 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
teplizumab 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
enoblituzumab 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
MGD-006 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
MGD-007 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
MGD-009 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
MGD-010 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
MGA-012 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
MGD-013 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
MGD-014 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Monoclonal Antibodies to Target DR5 for Oncology 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Monoclonal Antibodies to Target EphA2 and CD3 for Breast Cancer 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Monoclonal Antibodies to Target IL13Ralpha2 and CD3 for Melanoma, Glioblastoma Multiforme and Medulloblastoma 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Monoclonal Antibodies to Target ROR1 and CD3 for Oncology 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Monoclonal Antibody Conjugate to Target B7-H3 for Oncology 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
MacroGenics, Inc. - Pipeline Analysis 41
MacroGenics, Inc. - Pipeline Products by Target 41
MacroGenics, Inc. - Pipeline Products by Route of Administration 43
MacroGenics, Inc. - Pipeline Products by Molecule Type 44
MacroGenics, Inc. - Pipeline Products by Mechanism of Action 45
MacroGenics, Inc. - Recent Pipeline Updates 47
MacroGenics, Inc. - Dormant Projects 54
MacroGenics, Inc. - Company Statement 55
MacroGenics, Inc. - Locations And Subsidiaries 58
Head Office 58
Other Locations & Subsidiaries 58
Appendix 59
Methodology 59
Coverage 59
Secondary Research 59
Primary Research 59
Expert Panel Validation 59
Contact Us 59
Disclaimer 60

List of Tables

MacroGenics, Inc., Key Information 6
MacroGenics, Inc., Key Facts 6
MacroGenics, Inc. - Pipeline by Indication, 2016 8
MacroGenics, Inc. - Pipeline by Stage of Development, 2016 11
MacroGenics, Inc. - Monotherapy Products in Pipeline, 2016 12
MacroGenics, Inc. - Partnered Products in Pipeline, 2016 13
MacroGenics, Inc. - Partnered Products/ Combination Treatment Modalities, 2016 14
MacroGenics, Inc. - Out-Licensed Products in Pipeline, 2016 15
MacroGenics, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2016 16
MacroGenics, Inc. - Phase III, 2016 17
MacroGenics, Inc. - Phase II, 2016 18
MacroGenics, Inc. - Phase I, 2016 19
MacroGenics, Inc. - Preclinical, 2016 20
MacroGenics, Inc. - Pipeline by Target, 2016 42
MacroGenics, Inc. - Pipeline by Route of Administration, 2016 43
MacroGenics, Inc. - Pipeline by Molecule Type, 2016 44
MacroGenics, Inc. - Pipeline Products by Mechanism of Action, 2016 46
MacroGenics, Inc. - Recent Pipeline Updates, 2016 47
MacroGenics, Inc. - Dormant Developmental Projects,2016 54
MacroGenics, Inc., Other Locations 58
MacroGenics, Inc., Subsidiaries 58